• 前莫德納腫瘤轉化醫學負責人Lakshmi Srinivasan博士、前莫德納腫瘤疫苗研究及早期臨床轉化負責人Brandon Coder博士加盟雲頂新耀
• 兩位科學家的加入將進一步助力雲頂新耀mRNA產品管線的全球臨床開發，包括計劃於2026年第四季度啟動個性化腫瘤治療性疫苗EVM16 Ib期研究者發起的臨床試驗（IIT）、於2027年初在美國遞交新藥臨床試驗申請（IND），以及預計於2027年第一季度完成通用型腫瘤治療性疫苗EVM14 I期臨床研究

上海2026年10月9日 /美通社/ -- 雲頂新耀（HKEX 1952.HK）是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司，今日宣佈任命Lakshmi Srinivasan博士擔任高級副總裁、轉化醫學負責人，Brandon Coder博士擔任轉化科學與早期研究副總裁。此次任命將進一步強化雲頂新耀mRNA技術平台的全球研發能力與國際合作佈局。未來，公司將持續匯聚國際化頂尖人才，整合研發資源，加速全球創新戰略落地。

兩位新任高管均擁有深厚的行業經驗和專業背景，此前曾在莫德納等全球領先的生物製藥企業負責腫瘤疫苗研發，具備從早期發現到臨床轉化及臨床開發的完整實戰經驗。兩位資深科學家將在雲頂新耀管理層的領導下，圍繞公司全球mRNA的研發戰略，重點推動mRNA技術平台在美國的臨床開發及相關業務佈局，並與中國研發團隊密切協作，進一步賦能mRNA技術平台的進化。

雲頂新耀董事會主席吳以芳表示：「我們非常高興Srinivasan博士和Coder博士加入雲頂新耀。兩位資深科學家在腫瘤疫苗研發、轉化醫學及臨床開發領域擁有深厚經驗，將進一步強化公司的全球mRNA研發能力，助力推進自主mRNA技術平台及相關產品管線的全球臨床開發。此次任命體現了雲頂新耀持續匯聚全球頂尖人才、推進全球mRNA戰略的承諾。」

Lakshmi Srinivasan博士

Srinivasan博士擁有20年腫瘤免疫領域研發經驗，作為資深免疫學家，她長期致力於推動創新腫瘤免疫療法從早期發現研究走向臨床開發，在腫瘤疫苗、mRNA-LNP（脂質納米顆粒）技術、T細胞療法及轉化醫學開發等領域擁有豐富經驗，研發經驗覆蓋從臨床前研究到臨床概念驗證的多個階段。

加入雲頂新耀前，Srinivasan博士於2023年至2025年就職於莫德納（Moderna Therapeutics），曾任執行總監、腫瘤轉化醫學負責人；此前她曾任Repertoire Immune Medicines副總裁、臨床前科學與轉化醫學負責人，Neon Therapeutics（後併入BioNTech）轉化科學高級總監及賽諾菲（Sanofi）腫瘤藥物發現負責人。

Srinivasan博士長期從事個性化新抗原疫苗臨床轉化研究，並在該領域發表多篇高影響力學術論文。她作為通訊作者參與了NEO-PV-01的Ib期臨床研究，相關研究成果分別發表於《Cell》（2020年）^[1]和《Cancer Cell》（2022年）^[2]。此外，她也作為共同作者參與了莫德納 intismeran autogene（mRNA-4157/V940）的多篇代表性論文，包括發表於《Cancer Discovery》（2024年）的I期KEYNOTE-603研究中mRNA-4157/V940單藥及聯合帕博利珠單抗治療所誘導的T細胞應答^[3]；以及發表於《JCO Oncology Advances》（2026年）的mRNA-4157/V940聯合帕博利珠單抗治療切除後黑色素瘤的隨機IIb期 KEYNOTE-942研究3年隨訪結果^[4]。

Srinivasan博士曾在哈佛醫學院（Harvard Medical School）免疫疾病研究所（Immune Disease Institute）開展博士後研究，擁有印度科學研究院（Indian Institute of Science）微生物學與細胞生物學博士學位、賈瓦哈拉爾‧尼赫魯大學（Jawaharlal Nehru University）生物技術碩士學位及德裡大學（University of Delhi）生物化學學士學位。

Brandon Coder博士

Coder博士擁有超過11年的生物醫藥行業研發經驗，長期致力於推動T細胞免疫療法從早期發現研究走向IND申報及早期臨床概念驗證。他在腫瘤疫苗、mRNA/LNP平台技術及in vivo CAR療法領域擁有豐富經驗。

加入雲頂新耀前，Coder博士於2019年至2025年就職於莫德納，曾擔任莫德納腫瘤疫苗研究副科學總監等職務。在職期間，他曾是mRNA-4157/V940研究及全球藥理學負責人，並作為共同作者參與該項目KEYNOTE-603 I期臨床研究，相關研究成果發表於《Cancer Discovery》（2024年）^[3]。此外，他同時是莫德納共享抗原腫瘤疫苗mRNA-4359和mRNA-4106共享抗原發現及疫苗設計框架的共同發明人，並負責相關研發工作。

此前，Coder博士還曾任Advaxis Immunotherapies腫瘤免疫研發副總監，負責個性化及現貨型腫瘤疫苗的研發。

Coder博士擁有美國北德克薩斯大學健康科學中心（University of North Texas Health Science Center）生物醫學科學博士學位，研究方向為免疫學與遺傳學，並擁有德州理工大學（Texas Tech University）生物學學士學位。

關於雲頂新耀mRNA技術平台

作為全球少數擁有全流程、自主可控mRNA技術平台的生物製藥公司之一，雲頂新耀已構建起涵蓋抗原設計、mRNA序列優化、脂質納米顆粒（LNP）靶向遞送技術到產業化生產的完整產業鏈平台，擁有mRNA平台價值鏈端到端的能力，並成功實現臨床驗證。

雲頂新耀依托業內領先且完全整合的AI+mRNA平台，不僅可實現規模化生產，還擁有強大的知識產權組合。公司已建立並持續優化自主的LNP遞送技術平台，已在可電離脂質與隱形脂質方向形成專利群，擁有超過600種內部專有脂質分子，滿足多類型項目需求。通過自研的第三代AI算法的加持，顯著提升了mRNA的表達水平，為mRNA腫瘤疫苗的開發奠定了堅實基礎。

基於自主知識產權的AI+mRNA平台，雲頂新耀正多路徑推進mRNA腫瘤治療性疫苗和自體生成CAR-T平台，治療腫瘤及自身免疫疾病：

• 個性化腫瘤治療性疫苗EVM16完成首次人體臨床數據讀出，顯示出良好的安全性、耐受性、顯著的免疫原性及積極的初步療效信號，部分數據已於2026年美國癌症研究協會（AACR）年會上公佈。EVM16計劃於2026年第四季度啟動IIT（研究者發起的臨床試驗） Ib期臨床研究，並在Ia研究基礎上，開展新的適應症擴展隊列，進行有效性探索；並計劃於2027 H1遞交美國食品藥品監督管理局（FDA）新藥臨床試驗申請（IND）。
• 通用現貨型腫瘤相關抗原（TAA）疫苗EVM14，繼2025年相繼獲得美國FDA及中國國家藥品監督管理局「雙重IND」批准後，公司將於2027年第一季度完成臨床I期單藥劑量遞增。
• 自體生成CAR-T療法EVM18已啟動針對自身免疫疾病的IIT研究，同時公司正穩步推進其全球IND申報工作。

參考文獻

1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020
2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022
3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discovery, 2024
4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO advances, 2026

關於雲頂新耀
雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、歐盟和WHO標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明
本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

• Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines
• Appointments support continued advancement of Everest's mRNA pipeline, including a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026, U.S. IND submission in early 2027, and EVM14 Phase 1 study completion in Q1 2027

SHANGHAI, Oct. 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The appointments further strengthen the Company's global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. The Company will continue to invest in world-class talent to accelerate the development of its mRNA programs and to realize the platform's potential for global innovation.

Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. At Everest, they will drive clinical development of the Company's mRNA programs and expand Everest's presence in the United States, in line with the Company's global mRNA R&D strategy, while working closely with the China R&D team.

"We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest as we continue to strengthen our global mRNA R&D capabilities," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy."

Lakshmi Srinivasan, PhD

Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept.

Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics (later acquired by BioNTech), and Sanofi Oncology.

Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020)^[1] and Cancer Cell (2022),^[2] and co-authored publications on Moderna's intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024)^[3]  and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026).^[4] 

Dr. Srinivasan conducted postdoctoral research at the Immune Disease Institute at Harvard Medical School. She holds a PhD in Microbiology and Cell Biology from the Indian Institute of Science, a master's degree in biotechnology from Jawaharlal Nehru University, and a bachelor's degree in biochemistry from Delhi University.

Brandon Coder, PhD

Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies.

Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), where he co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024).^[3]  He also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106.

Previously, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. He holds a PhD in Biomedical Sciences, with a focus on immunology and genetics, from the University of North Texas Health Science Center and a bachelor's degree in biology from Texas Tech University.

About Everest's mRNAPlatform

Everest has built an industry-leading and fully integrated AI+mRNA platform that accelerates mRNA product development.

As one of the few global biopharmaceutical companies with a fully integrated and proprietary mRNA platform, Everest has built end-to-end capabilities across the entire value chain, covering antigen design, sequence optimization, LNP delivery, and scalable manufacturing. Everest has established and optimized its proprietary LNP delivery system, with patent coverage including ionizable lipids and stealth lipids. The internal lipid library (>600 lipids) supports multiple programs, including vaccines and in vivo CAR-T therapies. Backed by third-generation AI algorithms, Everest's AI+mRNA platform significantly boosts expression and immunogenicity, laying a solid foundation for mRNA-based cancer vaccine development.

Leveraging its proprietary AI+mRNA platform, Everest is advancing multiple mRNA therapeutic vaccine and in vivo CAR-T programs across oncology and autoimmune diseases.

• EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, a Phase 1b investigator-initiated trial (IIT) of EVM16 is planned in Q4 2026, with new indication expansion cohorts expected to further explore efficacy. The Company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027.
• EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China's National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.
• EVM18, an in vivo CAR-T therapy, is being evaluated in an IIT in autoimmune diseases, with global IND filing underway.

Reference

1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020
2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022
3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discovery, 2024
4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology advances, 2026

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates,""confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Current Mavericks and Rockets players and NBA legends join together
 to engage with Macao youth and inspire positive growth

MACAO, Oct. 9, 2026 /PRNewswire/ -- Ahead of The NBA China Games 2026, Sands China and NBA Cares held the Tip-OffDay as part of the "NBA Cares x Sands Cares Community Impact Week 2026" on Oct. 8 at The Venetian Arena. Embodying a shared spirit of care for the community, the event brought together around 400 participants, including current players from the Dallas Mavericks and the Houston Rockets; NBA executives, legends and coaches; executives and team members from Las Vegas Sands and Sands China, members of local school basketball teams, and local and international media. Together, they extended the impact of world-class basketball event beyond the court and into the community. Through personal sharing by NBA players, a basketball clinic, and goodie bag packing, the event brought energy, care and warmth to different sectors of the Macao community.

During the event, the Mavericks and Rockets players took on the role of youth mentors, engaging with students from two championship teams of the Macao Inter-School Basketball Competition: the Girls D Division team of Keang Peng School and Boys D Division team of Colégio dom Bosco (Yuet Wah). The NBA players also shared with local students the journeys of pursuing their dreams and experiences from their professional basketball careers, inspiring local students through the perseverance, determination and relentless dedication that underpin the success of elite athletes. Players and coaches from both NBA teams then led local students in a basketball clinic on the NBA court at The Venetian Arena, providing skills demonstrations and hands-on coaching in practical techniques.

Throughout the clinic, players engaged closely with the students, instilling the values of sportsmanship and teamwork. The event also offered Macao youth a valuable opportunity to learn directly from world-class basketball professionals, enhancing their basketball skills, broadening their horizons and inspiring them to pursue their aspirations and strive for excellence.

The Tip-Off event was also attended by two NBA legends: Yao Ming, eight-time NBA All-Star, five-time All-NBA Team, and 2016 Basketball Hall of Fame Inductee, as well as chairman of the Yao Foundation, and Shawn Marion, 2011 NBA champion, four-time NBA All-Star and two-time All-NBA Team. Both legends engaged with participants on-site, bringing further care and inspiration to the Impact Week.

Patrick Dumont, chairman of the board and chief executive officer of Las Vegas Sands Corp., and chairman of the board and non-executive director of Sands China Ltd., and governor of the Dallas Mavericks, said: "For more than two decades, we have grown alongside Macao and remained steadfast in our confidence in the city. For us, the value of major international sporting events extends well beyond what takes place inside the arena. Their lasting significance lies in their ability to contribute to social progress and the development of the city. Last year, we brought The NBA China Games back to Macao, adding to the city's growing portfolio of internationally renowned sporting events, while harnessing the power of sport to bring communities together, inspire young people and foster international exchange. This year, we are once again bringing together Sands Cares and NBA Cares to extend the impact of this major sporting event into the Macao community, enabling people of different ages, backgrounds and sectors to experience the spirit and positive energy of the NBA.

"We sincerely thank the Central People's Government, the Macao SAR Government and all sectors of the community for their longstanding support, which enables us to continue extending the benefits of major events throughout the community. Looking ahead, we will continue to leverage the international network of Las Vegas Sands and Sands China's integrated resort platform and pursue innovative, forward-looking approaches to further deepening the cross-sector 'Tourism+' development, supporting the development of a harmonious and inclusive community in Macao, and injecting continued momentum into Macao's position as a World Centre of Tourism and Leisure."

Adam Silver, commissioner of the NBA, said: "I want to particularly thank Patrick Dumont and Sands China for all they have done to make this event possible and the NBA players and teams for making this trip and being here. This means a lot to all of us and so much to the Macao community. There is no substitute for experiencing Macao in person. And to all the boys and girls here today, this event is really about you. Wherever the NBA goes around the world, we want to create opportunities for young people who love the game. Basketball teaches teamwork, respect and discipline, and these are lessons that can help you achieve whatever goals you set for yourselves in life, not just in basketball. My message to all of you is to dream big. That's what so many great NBA players did. They had a dream and pursued it. So take advantage of the opportunity to learn from the inspiring people around you today, and use the lessons you gain through sports to pursue your own dreams."

Patrick Fertitta, vice chairman of the Houston Rockets and Comets, said: "On behalf of the Houston Rockets, I would like to express our sincere appreciation to Adam Silver, Patrick Dumont along with Sands China, as well as all our partners for making this meaningful week possible. We are delighted to join the Mavericks and the wider NBA community in Macao, not only to celebrate the game of basketball, but also to demonstrate how sport can inspire young people and create a positive impact in the community. We are especially honoured to have Hall of Famer Yao Ming with us today. His remarkable legacy extends far beyond the game, and his influence continues to bring people together across cultures and generations. To the young people here today, I encourage you to dream big, work hard and believe in yourselves. Basketball teaches us the values of teamwork, perseverance and giving back to others. I hope these are lessons you will carry with you, both on and off the court, as you pursue your aspirations and contribute positively to your communities."

In addition, NBA players joined local students, executives from Las Vegas Sands and Sands China, and Sands Cares Ambassadors in assembling goodie bags to share care and warm wishes with the community. The bags contained towels, notebooks, commemorative water bottles provided by the Dallas Mavericks, sports wristbands from the Houston Rockets, G Bear blind boxes and other gifts. Some of the care packages were presented to the students on-site, while the remainder will be distributed to people in need within the community during subsequent Impact Week activities, extending the spirit of care to more members of the local community.

Following the Tip-Off event, the Dallas Mavericks and the Houston Rockets each held pre-game training sessions at The Venetian Arena, making final preparations for their first matchup the following day (Oct. 9). The two NBA teams fine-tuned their tactics as they prepared to take to the court at their best.

Guests attending the Tip-Off event included: Adam Silver, commissioner of the NBA; Mark Tatum, deputy commissioner and chief operating officer of the NBA; Michael Ma, CEO of NBA Asia Pacific; Wayne Chang, managing director of NBA Asia; Kathy Behrens, president of social responsibility and player programs of NBA; NBA legends Shawn Marion and Yao Ming; Dr. Miriam Adelson, co-founder of Las Vegas Sands Corp.; Patrick Dumont, chairman of the board and chief executive officer of Las Vegas Sands Corp., and chairman of the board and non-executive director of Sands China Ltd., and governor of the Dallas Mavericks; Dr. Wilfred Wong, executive vice chairman of Sands China Ltd.; Grant Chum, chief executive officer and executive director of Sands China Ltd.; Hubert Wang, chief operating officer of Sands China Ltd.; Dave Sun, executive vice president and chief financial officer of Sands China Ltd. and managing director of Venetian Macau Limited.

The "NBA Cares x Sands Cares Community Impact Week 2026" is taking place over five consecutive days, Oct. 7-11, featuring a diverse programme of activities focused on youth development, healthy living and community inclusion. Current NBA players and legends will engage with communities across Macao, with the initiative seeking to extend the impact of the NBA sporting event into the community and enable more Macao residents to experience the positive energy and excitement generated by the world-class basketball event.

The Impact Week continues on Oct. 9 with "School Day" at Yuet Wah College in Macao. NBA legends and coaches will visit the school to engage directly with local students through basketball training and interactive exchanges, helping young participants enhance their basketball skills and inspiring greater enthusiasm for sport.

"NBA Cares x Sands Cares Community Impact Week 2026" is part of Sands Cares, the global corporate citizenship programme of Sands China's parent company. As an important stakeholder in the Macao community, Sands China has actively fulfilled its corporate social responsibility for more than two decades. Through the programme, the company strives to connect with and serve the community, give back to society, and work alongside different sectors to build a more vibrant and inclusive Macao community.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Sands Cares

A firm believer in the importance of corporate social responsibility, Sands China Ltd. engages with the local Macao community as a part of Sands Cares – the charitable giving programme of parent company Las Vegas Sands Corp. Sands Cares integrates the company's philanthropic work worldwide in four key areas: financial giving, community problem solving and collaboration, in-kind donations, and team member volunteerism.

Key areas of Sands Cares in Macao include the Sands Cares Ambassador programme for volunteering in the local community; charitable contributions to NGOs and community organisations; and sponsorship of community events.

For more information, please visit www.sands.com/sands-cares/ 

About NBA Social Impact & Inclusion and NBA Cares

NBA Social Impact & Inclusion drives change on issues facing fans and communities by advancing needed resources and proven partners. We create data-driven strategies and programming to empower colleagues to bring their best self. NBA Cares works with NBA players and teams to highlight important issues through the NBA's digital, social and broadcast channels, live events and partnerships.

Media contacts:

Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

獨行俠與火箭隊現役球員及NBA傳奇球星共同參與
與本澳青年互動交流  傳遞正向成長力量

澳門2026年10月8日 /美通社/ -- NBA中國賽2026開賽前夕，金沙中國聯同NBA關懷行動（NBA Cares）於今天假威尼斯人綜藝館舉行「NBA關懷行動 × 金沙關懷籃球公益周2026」之啟動日。活動充分體現社區關愛精神，聯動社區各界關愛力量，匯聚達拉斯獨行俠隊（Dallas Mavericks）和侯斯頓火箭隊（Houston Rockets）現役球員、NBA管理層、傳奇球星及教練、拉斯維加斯金沙集團及金沙中國管理層和團隊成員、本澳學校籃球隊成員、以及中外傳媒代表等共約400人出席，共同將世界級籃球盛事的影響力由球場延伸至社區，並透過NBA球員親身分享、籃球訓練營及愛心禮包製作等活動，向澳門社區各界傳遞活力、關愛與溫暖。

活動上，兩支即將於NBA中國賽交鋒的球隊化身青年導師，與來自澳門學界籃球比賽冠軍隊伍，包括鏡平學校女子D組及鮑思高粵華小學男子D組的學生交流互動，分享追夢歷程及籃球職業生涯點滴，讓一眾青少年從中體會頂尖運動員背後的堅毅意志與不懈努力。其後，兩支NBA球隊的球員及教練親自在澳門威尼斯人綜藝館的NBA賽場上，帶領本澳學生投入籃球訓練營，透過技術示範及指導，傳授實戰技巧。NBA球員與學生深入切磋交流，展現團隊合作的體育精神與正能量，氣氛熾熱融洽。活動讓本澳青年得以近距離向世界級籃球精英取經，難能可貴的經驗不僅提升球技，更從交流中開拓視野、啟發夢想，汲取追求卓越的正向力量。

啟動日亦獲NBA傳奇球星、八屆NBA全明星、五度入選All-NBA陣容、2016年入選籃球名人堂、姚基金理事長姚明，以及NBA傳奇球星、2011年NBA總冠軍、四屆NBA全明星、兩度入選All-NBA陣容的夏恩‧馬利安（Shawn Marion）親臨支持，與現場參加者交流分享，共同為公益周注入更多關愛與啟發。

拉斯維加斯金沙集團董事會主席兼行政總裁、金沙中國有限公司董事會主席兼非執行董事、達拉斯獨行俠隊班主Patrick Dumont表示：「二十多年來，我們一直與澳門並肩同行，對澳門充滿堅定信心。對我們而言，國際體育盛事的價值不只體現在場館內，更在於其推動社會進步和城市發展的長遠力量。去年，我們將NBA中國賽再次帶到澳門，不僅為澳門增添享譽國際的體育盛事名片，更充分發揮體育運動在凝聚社區、啟迪青年以及促進國際交流方面的積極作用。今年我們繼續聯動金沙關懷及NBA關懷行動，將盛事效應延伸至澳門社區，讓不同年齡、背景及界別的人士共同感受NBA所傳遞的體育精神與正向能量。衷心感謝中央人民政府、澳門特區政府及社會各界的長期支持，讓我們得以持續把盛事效益輻射至社區各個層面。未來，我們將繼續發揮金沙集團的國際網絡及金沙中國的綜合度假村平台優勢，持續以創新及前瞻思維深化『旅遊+』融合發展，支持澳門建設和諧共融的社區，並為澳門『世界旅遊休閒中心』定位持續注入動能。」

NBA總裁亞當‧蕭華（Adam Silver）表示：「我謹此衷心感謝Patrick Dumont及金沙中國為促成這次盛事所付出的努力，亦感謝各位NBA球員及代表專程來到澳門參與這次活動。你們的到來對我們所有人以及澳門社區而言均意義重大。我相信親身來到澳門，是無可取代的寶貴體驗。今天這項活動真正的主角是在場的每一位小朋友；無論NBA走到世界哪個地方，我們都希望為熱愛籃球的年輕人創造更多機會。籃球讓我們學會團隊合作、尊重與紀律，而這些從球場上學到的寶貴價值，不只適用於籃球，更能幫助大家實現人生不同階段的目標。我的寄語是要勇於追夢，許多偉大的NBA球員都是如此，他們心懷夢想，並為之努力。因此，希望大家珍惜今天身邊這些充滿啟發的人物，把從體育和籃球中學到的寶貴精神，化為追尋自己夢想的力量。」

侯斯頓火箭隊及侯斯頓彗星隊副主席 Patrick Fertitta 表示：「我謹代表侯斯頓火箭隊，衷心感謝Adam Silver、Patrick Dumont、金沙中國及一眾合作夥伴的鼎力支持，促成這個別具意義的籃球公益周。我們很高興能與達拉斯獨行俠隊及NBA大家庭聚首澳門，不僅共同感受籃球運動的魅力，更希望藉着體育的力量啟發青年，為社區帶來積極而深遠的影響。我們亦非常榮幸能與籃球名人堂成員姚明一同參與今天的活動。他在籃球界所留下的非凡影響力早已超越賽場，並持續透過籃球連繫不同文化及世代。我亦希望勉勵在場的青年勇於追夢、努力不懈，並相信自己。籃球讓我們體會團隊合作、堅毅不屈及回饋社會的重要價值。我期望大家無論在球場內外，都能將這些寶貴精神延續下去，在追尋理想的同時，積極貢獻社會，為社區帶來正面力量。」

此外，一眾NBA球員聯同本澳學生、拉斯維加斯金沙集團及金沙中國管理層、金沙中國關懷大使於現場攜手製作愛心禮包，向社區傳遞關懷與祝福。禮包內備有毛巾、筆記本、由達拉斯獨行俠隊提供的紀念水樽、以及侯斯頓火箭隊送出的運動腕帶；以及G Bear盲盒等禮品。部分愛心禮包於現場送贈予參與學生，其餘將於公益周後續活動中派發予社區有需要人士，將關愛延伸至更多社群。

啟動日活動結束後，達拉斯獨行俠隊和侯斯頓火箭隊兩支NBA勁旅分別在澳門威尼斯人綜藝館進行賽前訓練，為翌日（9日）上演的首場賽事作最後備戰，調整狀態、部署戰術，務求以最佳表現踏上賽場。

出席啟動日的嘉賓包括：NBA總裁亞當‧蕭華（Adam Silver）；NBA副總裁兼營運長馬克‧塔圖姆 （Mark Tatum）；NBA亞太區行政總裁馬曉飛；NBA亞洲區董事總經理張文正；NBA社會責任及球員項目總裁Kathy Behrens；NBA傳奇球星夏恩‧馬利安（Shawn Marion）、姚明；拉斯維加斯金沙集團共同創辦人瑪莉安・艾德森醫生；拉斯維加斯金沙集團董事會主席兼行政總裁、金沙中國有限公司董事會主席兼非執行董事、達拉斯獨行俠隊班主Patrick Dumont；金沙中國有限公司行政副主席王英偉博士；行政總裁兼執行董事鄭君諾；首席營運總裁王志琪；以及行政副總裁兼財務總裁、威尼斯人澳門股份有限公司常務董事孫敏其。

「NBA 關懷行動 × 金沙關懷籃球公益周」於10月7日至11日一連五日舉行，涵蓋青年發展、健康生活及社區共融等多元活動，邀請NBA現役及傳奇球星走進社區，與本澳廣泛社群交流互動，致力將NBA體育盛事的影響力延伸至社區，讓本澳更多市民感受世界級籃球盛事所帶來的正能量和熾熱氣氛。

明天（10月9日）將於澳門粵華中學舉行公益周活動「校園日」。屆時，NBA傳奇球星及教練將走進校園，與本澳學生展開近距離交流，並透過籃球訓練及互動交流，增進青少年籃球技巧，激發對體育運動的熱情。

「NBA關懷行動×金沙關懷籃球公益周」為母公司「金沙關懷」企業公民計劃的一部分。作為本澳社區的重要持份者，金沙中國二十多年來積極踐行企業社會責任，旨在透過計劃連結社區、服務社群，回饋社會，與各界攜手共建更具活力、共融精神的澳門社區。

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

「金沙關懷」計劃

金沙中國有限公司不遺餘力推動及履行企業社會責任，積極參與母公司拉斯維加斯金沙集團所設立的「金沙關懷」企業公民計劃回饋澳門社區。「金沙關懷」計劃引領集團在全球各地開展慈善工作，包括經濟援助、社區援助及合作、物資捐贈及員工參與義工活動等。

「金沙關懷」企業公民計劃在澳門的主要項目包括：在澳門社區開展義務工作的金沙中國關懷大使計劃、向非牟利機構及社會企業捐款以及社區活動贊助等。

如欲索取更多相關資訊，請瀏覽網頁https://www.sands.com/sands-cares/。

關於NBA社會影響與包容度及NBA關懷

NBA社會影響與包容部門通過整合所需資源和可靠的合作夥伴，制定數據驅動的策略和項目，以應對球迷和社區面臨的問題，影響NBA生態系統，並賦能同事以最佳狀態投入工作，推動全球範圍內的成功。NBA關懷行動與NBA球員和球隊合作，通過NBA的數字、社交媒體和電視轉播渠道、現場活動及合作夥伴關係，聚焦重要社會議題。

傳媒查詢：

金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

• SYCUME^® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED)

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced today that its independently developed recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME^® (Teprotumumab N01 Injection, R&D code: IBI311), has achieved its primary study endpoint at Week 24 in a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study (RESTORE-3) in Chinese participants with inactive thyroid eye disease (TED). In this study, SYCUME^® demonstrated remarkable efficacy in reducing proptosis in participants with inactive TED, with a favorable safety profile.

SYCUME^® is the first IGF-1R antibody drug in China and the second one approved worldwide, filling a 70-year treatment gap in the domestic TED field. Officially included in China's National Reimbursement Drug List on January 1, 2026, SYCUME^® substantially alleviates the financial burden on patients compared to the high cost of overseas counterparts, significantly enhancing drug accessibility. Patients with inactive TED account for approximately two-thirds of the overall TED population¹. Thus, the positive Phase 3 clinical trial results in inactive TED participants mark another milestone breakthrough for SYCUME^® in full-course disease management and precision therapy for TED, providing novel clinical evidence for the treatment of inactive TED in China.

RESTORE-3 is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of IBI311 in Chinese participants with inactive TED. A total of 116 eligible participants were randomized in an approximate 2:1 ratio to receive either IBI311 or placebo. The primary efficacy endpoint was the proptosis response rate of the study eye at Week 24, and the key secondary endpoint was the change from baseline in proptosis of the study eye at Week 24.

The study enrolled 116 participants with inactive TED (bilateral CAS ≤ 2 points), with a mean disease duration of 4.3 years, a baseline mean proptosis distance of 22.16 mm in the study eye, and approximately 74.1% of patients presenting with a baseline CAS of 0 or 1 point. Within this baseline population, IBI311 demonstrated clinically meaningful efficacy, successfully achieving all primary and key secondary endpoints:

• Primary Endpoint Achieved: At Week 24, the proptosis response rate in the study eye was significantly higher in the IBI311 group compared with the placebo group (60.4% vs. 23.5%; treatment difference: 36.9 percentage points; p = 0.0003).
• Key Secondary Endpoint Achieved: At Week 24, the least squares mean (LS Mean) change from baseline in study eye proptosis distance in the IBI311 group was -1.88 mm, demonstrating statistically significant superiority over placebo (-0.88 mm; treatment difference: -1.00 mm; p < 0.0001).
• Multidimensional Secondary Benefits: At Week 24, the proptosis response rate in non-study eyes was higher in the IBI311 group than in the placebo group (46.0% vs. 19.8%; p = 0.0071). The LS Mean change from baseline in proptosis distance in non-study eyes reached -1.77 mm in the IBI311 group versus -0.91 mm in the placebo group (p < 0.0001), consistent with the trend observed in study eyes.
• Favorable Safety Profile: During the double-blind treatment and follow-up period, IBI311 exhibited good safety and tolerability. Most treatment-emergent adverse events were mild to moderate in severity, and no new safety signals were identified.

The follow-up of this study is still ongoing, and the complete data will be published in future academic conferences or peer-reviewed academic journals. Although the baseline mean proptosis in RESTORE-3 was lower than that in the TEPEZZA^® study (indirect comparison), the proptosis response rate and the proptosis reduction of IBI311 were generally consistent with TEPEZZA^®'s data² in inactive TED.

Professor Zhongyan Shan from the First Hospital of China Medical University, Lead Principal Investigator of the study stated: "For a long time, effective pharmacological interventions for inactive TED have been lacking. Following the resolution of acute inflammation, patients frequently suffer from persistent proptosis and facial disfigurement. At this stage, surgical intervention has been virtually the sole recourse, leading many patients to forgo treatment and endure the chronic burden of the disease. Results from this trial confirm that SYCUME^® yields robust and clinically meaningful reductions in proptosis even in patients with chronic, inactive TED. This not only validates the therapeutic value of targeting IGF-1R in long-duration inactive TED, but also offers tens of thousands of chronic TED sufferers and clinicians a novel non-surgical treatment paradigm—promising new hope and restored quality of life for patients with inactive TED."

Dr. Lei Qian, Chief R&D Officer (General Biomedicine Pipeline) of Innovent Biologics indicates: "As the first targeted therapy for TED approved and successfully incorporated into the NRDL in China, SYCUME^® has already benefited a vast number of TED patients. With these positive Phase III trial results, SYCUME^® now achieves comprehensive disease coverage ranging from 'early acute control' to 'chronic phase tissue remodeling.' This milestone underscores Innovent's steadfast commitment to serving TED patients while reinforcing SYCUME^®'s leading position in this therapeutic space. We will work closely with medical experts to rapidly translate these clinical findings into standard clinical practice, benefiting a broader patient population and elevating the overall standard of TED diagnosis and care in China."

About Thyroid Eye Disease (TED)

TED, an autoimmune disease involving ocular tissues, is the most common orbital disease in adults. TED affects approximately 25% to 40% of Graves'disease patients, as well as individuals with other thyroid diseases and even those with normal thyroid function³.

The annual incidence of TED is estimated at 16 per 100,000 women and 2.9 per 100,000 men, with a prevalence of 0.1 to 0.3%^4,5. Based on disease severity, TED can be classified into mild, moderate to severe, or sight-threatening. While TED is more common in women, severe cases occur more frequently in men. The exact pathogenesis of TED is not fully understood, but multiple studies suggest that orbital fibroblasts (OFs) in muscle fibers and orbital connective tissue play a key role in orbital soft tissue hyperplasia in TED⁶.

The natural progression of TED is divided into active and inactive stages⁷. Common symptoms include dry eye, foreign body sensation, photophobia, lacrimation, diplopia, and pressure behind the eyes. Typical signs include upper eyelid retraction, proptosis, periorbital soft tissue congestion and edema, and ocular motility disorders. While TED is usually mild to moderate-to-severe, about 3-5% of patients develop sight-threatening TED, which can result in vision-threatening corneal ulcers or compressive optic neuropathy⁸. In addition to affecting appearance and visual function, TED significantly impacts patients' social functioning and quality of life. Historically, inactive TED was deemed non-responsive to medical therapies. Patients with proptosis, strabismus, or eyelid disfigurement affecting aesthetics, visual function, or quality of life typically relied on corrective surgeries, including strabismus surgery, eyelid reconstruction, and orbital decompression⁹. Nevertheless, these surgical procedures are complex, less accessible, and yield only partial clinical improvement, making full restoration to pre-disease status exceptionally difficult to achieve. Recent Chinese and international treatment guidelines and joint consensus have recommended the use of IGF-1R-targeted biologics as a second-line treatment for TED^9-11. Particularly for patients with significant proptosis or diplopia, IGF-1R-targeted biologics can be considered the first-line treatment in such cases¹¹.

About SYCUME^®

SYCUME^® (teprotumumab N01) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody developed by Innovent for the treatment of TED. IGF-1R is a transmembrane tyrosine kinase receptor involved in development, metabolism, and immune regulation, and is overexpressed in Orbital Fibroblasts (OFs), B cells, and T cells of TED patients¹². SYCUME^® blocks the activation of IGF-1R signaling pathway mediated by IGF-1 and related ligands or agonistic antibodies, reducing the expression of downstream inflammatory factors. This inhibition decreases the synthesis of hyaluronic acid and other glycosaminoglycans caused by OFs activation, thereby alleviating inflammation. It also prevents OFs differentiation into adipocytes or myofibroblasts, consequently reducing disease activity and improving clinical manifestations such as proptosis, diplopia, orbital congestion and edema.

In March 2025, SYCUME^® was approved by the NMPA for the treatment of TED. On January 1, 2026, SYCUME^® was officially included in the National Reimbursement Drug List.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases.  Innovent has launched 20 products in the market. It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

REFERENCES

1. Schuh A, Ayvaz G, Baldeschi L, et al. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). Br J Ophthalmol. 2024 Jan 29;108(2):294-300.
2. Douglas RS, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab. 2023 Dec 21;109(1):25-35.
3. Li Z, Cestari D M, Fortin E. Thyroid eye disease: what is new to know? Curr Opin Ophthalmol. 2018;29(6):528-534.
4. Bartley G. The epidemiological characteristics and clinical course of ophthalmology associated with autoimmune thyroid disease in Olmsted Country, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588.
5. Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353-60.
6. Ali F, Chorsiya A, Anjum V, Ali A. Teprotumumab (TEPEZZA): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. Int Ophthalmol. 2021;41(4):1549-1561.
7. Dolman P J. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab.2012;26(3):229-248.
8. Bahn R S. Graves' ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
9. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67.
10. 中华医学会眼科学分会眼整形眼眶病学组, 中华医学会内分泌学分会甲状腺学组. 中国甲状腺相关眼病诊断和治疗指南 （2022年）.中华眼科杂志. 2022;58(9).
11. Burch HB, et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022;11(6):e220189.
12. Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008;181:5768-5774.

Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week

PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript's wet lab validation and data generation capabilities and NVIDIA's accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.

Up to six finalists will be selected for a GenScript-hosted pitch event during JPM Week in January before a panel of judges. The winning company will receive GenScript wet lab data credits and Brev credits from NVIDIA to support its development efforts. Applications opened today, and finalists will be confirmed in December.

AI is making therapeutic discovery more expansive than ever, giving scientists new ways to generate hypotheses, identify targets, and design candidates at unprecedented speed. The PitchFest is designed to channel that momentum by connecting emerging AI drug discovery and life science companies with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle.

"To harness the true potential of AI in life sciences, we must build an ecosystem where world-class computation meets trusted, scalable biological validation," said Ray Chen, President of GenScript Life Science Group. "Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence from computational promise to therapeutic progress. PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies."

Through the competition, GenScript will contribute sequence-to-data capabilities and experimental validation expertise, while NVIDIA will provide access to NVIDIA Inception, its free program that helps startups build, scale, and connect across the NVIDIA platform and ecosystem. Together, GenScript and NVIDIA will help selected startups move from promising AI-driven concepts toward stronger biological evidence, investor readiness, and potential partnerships.

Finalists will also be invited to GenScript's Biotech Global Forum, where they can engage with biotechnology executives, strategic partners, and industry leaders focused on the future of AI-enabled discovery.

Additional details on judging criteria, speakers, and investor participation will be announced in the coming weeks as the program helps AI-driven life science startups generate evidence, build industry relationships, and accelerate their own commercialization journeys.

About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners – from academic institutions to industry leaders – to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com.

Media Contacts:
Kate Grusich, GenScript Biotech Corporation
[email protected]

BEIJING, Oct. 8, 2026 /PRNewswire/ -- New Oriental Education & Technology Group Inc. ("New Oriental" or the "Company") (NYSE: EDU and SEHK: 9901), a provider of private educational services in China, today announced that it will hold its annual general meeting of shareholders at No. 6 Hai Dian Zhong Street, Haidian District, Beijing, People's Republic of China, on November 13, 2026 at 5:00 p.m. (local time).

No proposal will be submitted for shareholder approval at the annual general meeting. Instead, the annual general meeting will serve as an open forum for shareholders of record and beneficial owners of the Company's American depositary shares ("ADSs") to discuss Company affairs with management.

The board of directors of the Company has fixed the close of business on October 23, 2026 (Beijing time) as the record date (the "Record Date") for determining the shareholders entitled to receive notice of the annual general meeting or any adjournment or postponement thereof.

Holders of record of the Company's common shares at the close of business on the Record Date are entitled to attend the annual general meeting and any adjournment or postponement thereof in person. Beneficial owners of the Company's ADSs are welcome to attend the annual general meeting in person.

The Company has filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended May 31, 2026, with the U.S. Securities and Exchange Commission. The Form 20-F can be accessed on the Company's website at http://investor.neworiental.org, as well as on the SEC's website at http://www.sec.gov.

The Company has also published its annual report for Hong Kong purposes pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("HKEX"), which can be accessed on the Company's investor relations website at http://investor.neworiental.org as well as the HKEX's website at http://www.hkexnews.hk.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

For investor and media inquiries, please contact:

Ms. Rita Fong
FTI Consulting
Tel: +852 3768 4548
Email: [email protected]

Ms. Sisi Zhao
New Oriental Education & Technology Group Inc.
Tel: +86-10-6260-5568
Email: [email protected]

Former ByteDance intern Tian Keyu, who was dismissed for serious disciplinary violations, founded an AI startup focused on World Models, Bloomberg reported. The startup already secured backing from prominent investment institutions including 5Y Capital and IDG Capital, and is preparing to enter the World Models field being explored by AI researchers such as Fei-Fei Li and Yann LeCun.

Although the company remains at an early stage, has yet to determine a name and has not launched any products, it has already completed financing of nearly USD30 million, with a post-money valuation reaching USD200 million.

Investors include 5Y Capital and IDG Capital, both of which previously invested in Moonshot AI. Both institutions confirmed the investment to Bloomberg.

World Models have become a new hot investment theme. Advanced Micro Devices, Inc. (AMD.US) announced last month that it would acquire World Labs, the World Models company founded by Fei-Fei Li, for billions of USD.

In addition, a new AI model named Jev, with costs lower than traditional LLMs, also attracted investor interest, with the potential financing valuation of its developer exceeding USD10 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Amazon.com, Inc. (AMZN.US) founder Jeff Bezos said private space company Blue Origin may seek an IPO in the coming years after raising USD10 billion from external investors for the first time.

Blue Origin is a major competitor to Elon Musk's SpaceX (SPCX.US). Bezos said he has personally invested USD28 billion in Blue Origin since founding the company in 2000.

The Wall Street Journal had reported in September this year that Blue Origin's latest funding round valued the company at USD140 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Cui Dongshu, secretary-general of the China Passenger Car Association (CPCA), said global vehicle sales numbered 63.43 million units in 8M26, while global new energy passenger vehicle (NEV-PV) sales reached 15.7 million units, up 15% YoY.

Among them, NEV sales in August numbered 2.23 million units, up 16% YoY, with growth returning to historically normal levels. The penetration rate of NEVs reached 24.5% in 8M26, of which BEVs accounted for 17.3%, and PHEVs accounted for 7.5%. Hybrid vehicles achieved an outstanding 8% share.

In light of factors including high tariffs and price increases following the cancellation of NEV subsidies, US NEV sales in August sank 44% YoY to 110,000 units. US NEV sales in 8M26 totaled 820,000 units, down 31% YoY. Europe's NEV passenger vehicle sales reached 3.86 million units in 2025, representing a YoY hike of 960,000 units, or 33%. Preliminary statistics showed that Europe's NEV-PV sales in August grew 33% YoY to 320,000 units, while sales in 8M26 added 34% YoY to 3.12 million units.
~

AASTOCKS Financial News
Website: www.aastocks.com